6,963 publications from this institution
Section:ChooseTop of pageAbstract <<NEW BRONCHODILATORSSMOKING CESSATIONMEDIATOR ANTAGONISTSNEW ANTIINFLAMMATORY TREA...PROTEASE INHIBITORSMUCOREGULATORSALVEOLAR REPAIRROUTE OF DELIVERYFUTURE DIRECTIONSReferencesCITING ARTICLES
<b>Introduction:</b> Chronic obstructive pulmonary disease (COPD) is associated with accelerated ageing of the lung. In COPD, microRNA(miR)-21 is up-regulated in plasma and miR-34a in epithelial cells. Microfluidic technology enables multiplexing of miRNA assays with single cell analysis to absolutely quantify miRNAs in scarce samples. <b>Aim:</b> To develop a multiplex assay to absolutely quantify miR-21 and miR-34a molecules from the same cell <b>Methods:</b> A multiplex chip was microarrayed with miR-21 and miR-34a capture probes. Complimentary reporter probes were tagged with different fluorophores. Small airway fibroblasts (SAF) and epithelial cells (SAEC) (50 cells/experiment) were optically manipulated and lysed. Single miR-21 and miR-34a molecules released from the same cell were imaged using microscopy. <b>Results:</b> MiR-21 expression in COPD was significantly elevated (SAF: 83.5±1.2 x10<sup>3</sup> and SAEC: 102±0.9 x10<sup>3</sup>, p<0.05) compared to non-smokers (NS) (SAF: 27.5±0.3 x10<sup>3</sup> and SAEC: 23.5±0.4 x10<sup>3</sup>) molecules/cell. MiR-34a expression in COPD was significantly increased (SAF: 65.1±0.7 x10<sup>3</sup> and SAEC: 79.8±0.4 x10<sup>3</sup>, p<0.05) compared to NS (SAF: 3.1±0.01 x10<sup>3</sup> and SAEC: 7.42±0.1 x10<sup>3</sup>) molecules/cell. Both miRNAs expression were positively correlated in SAF and SAEC but reduced in COPD SAF (NS: r=0.81, p<0.0001 vs COPD: r= 0.66, p<0.0001, n=5) and SAEC (NS: r=0.86, p<0.0001 vs COPD: r=0.64, p<0.0001, n=5). <b>Conclusion:</b> Absolute expression of miRNAs can be quantified from the same cell using a microfluidic multiplex assay. Expression of miR-21 and miR-34a in a single cell are positively correlated but differ between COPD and NS subjects. Thus, this novel tool may be used to identify miRNAs as COPD biomarkers.
No abstract is provided for this article.
1 Our understanding of asthma and its therapy has changed markedly over the last few years, particularly with the application of molecular and cell biology and the discovery of new and more specific pharmacological tools. 2 Many inflammatory cells participate in the inflammatory process in asthma and mediate a complex mixture of mediators. Cytokines are of particular importance as mediators of chronic inflammation and the means by which cytokines amplify and perpetuate the inflammatory process is now emerging. Airway epithelial cells may be a particularly important source of cytokines and other mediators, such as nitric oxide and endothelin, and may be a major target cell for inhaled steroids, which are the most effective therapy for asthma currently available. 3 The inflammatory process in asthma results not only in bronchoconstriction, but also plasma exudation, the activation of neural mechanisms, mucus secretion. The chronic inflammation may lead to structural changes, including an increase in airway smooth muscle and fibrosis, that are essentially irreversible. There is increasing evidence that transcription factors, such as NF‐κB, play a pivotal role in the expression of inflammatory genes in asthma and may be the major molecular target for glucocorticoids.
No abstract is provided for this article.
Background Prompt revascularization is often required in acute coronary syndromes (ACS), whereas stable ischemic heart disease (SIHD) may allow for more measured procedural planning. Whether the acuity of presentation preferentially affects outcomes after coronary artery bypass grafting (CABG) versus percutaneous coronary intervention (PCI) in patients with left main coronary artery disease (LMCAD) is unknown. We investigated whether the acuity of presentation discriminated patients who derived a differential benefit from PCI versus CABG in the randomized Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial. Methods We used multivariable Cox models to assess the interaction between the acuity of presentation, type of revascularization and outcomes in patients with low or intermediate SYNTAX scores enrolled in EXCEL. Results At baseline, 1151 patients (60.7%) presented with SIHD and 746 patients (39.3%) presented with an ACS. The acuity of presentation was not associated with the primary endpoint of all-cause death, MI, or stroke at 3 years (multivariable adjusted hazard ratio [HR] 0.94; 95% CI 0.70–1.26, P = .64). The primary endpoint rate was similar in patients assigned to PCI versus CABG whether they presented with SIHD (adjusted HR 1.04; 95% CI 0.73–1.48]) or with ACS (HR 0.82; 95% CI 0.54–1.26) (P interaction = .34). Conclusions The acuity of presentation did not predict outcomes in patients with LMCAD undergoing revascularization, nor did it discriminate patients who derive greater event-free survival from PCI versus CABG.
Coronary computed tomography angiography (CTA) has shown great technological improvements over the last 2 decades. High accuracy of CTA in detecting significant coronary stenosis has promoted CTA as a substitute for conventional invasive coronary angiography in patients with suspected coronary artery disease. In patients with coronary stenosis, CTA-derived physiological assessment is surrogate for intracoronary pressure and velocity wires, and renders possible decision-making about revascularization solely based on computed tomography. Computed tomography coronary anatomy with functionality assessment could potentially become a first line in diagnosis. Noninvasive imaging assessment of plaque burden and morphology is becoming a valuable substitute for intravascular imaging. Recently, wall shear stress and perivascular inflammation have been introduced. These assessments could support risk management for both primary and secondary cardiovascular prevention. Anatomy, functionality, and plaque composition by CTA tend to replace invasive assessment. Complete CTA assessment could provide a 1-stop-shop for diagnosis, risk management, and decision-making on treatment.